S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Earnings Date, Estimates & Call Transcripts

$7.96
-0.05 (-0.62%)
(As of 05:11 PM ET)
Compare
Today's Range
$7.86
▼
$8.11
50-Day Range
$7.37
▼
$8.77
52-Week Range
$7.20
▼
$15.43
Volume
2.34 million shs
Average Volume
2.94 million shs
Market Capitalization
$1.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 3Estimated
Actual EPS
(May. 3)
-$0.28 Beat By $0.02
Consensus EPS
(May. 3)
-$0.30
Last Year's Q2 EPS
(5/5/2022)
-$0.40
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

BCRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BCRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioCryst Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20234($0.36)($0.16)($0.27)
Q2 20234($0.36)($0.20)($0.26)
Q3 20234($0.29)($0.18)($0.23)
Q4 20234($0.23)($0.18)($0.19)
FY 202316($1.24)($0.72)($0.95)

BCRX Earnings Date and Information

BioCryst Pharmaceuticals last posted its quarterly earnings data on May 3rd, 2023. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.02. The company had revenue of $68.80 million for the quarter, compared to analyst estimates of $71.44 million. Its quarterly revenue was up 37.9% on a year-over-year basis. BioCryst Pharmaceuticals has generated ($1.21) earnings per share over the last year (($1.21) diluted earnings per share). Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($1.03) to ($0.48) per share. BioCryst Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 3rd, 2023 based off prior year's report dates.

BioCryst Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/3/2023
(Estimated)		        
5/3/2023Q1 2023($0.30)($0.28)+$0.02($0.28)$71.44 million$68.80 million    
2/21/2023Q4 2022($0.19)($0.38)($0.19)($0.38)$74.18 million$79.50 million    
11/1/2022Q3 2022($0.32)($0.23)+$0.09($0.23)$73.45 million$75.83 million
8/4/2022Q2 2022($0.36)($0.32)+$0.04($0.32)$63.92 million$65.53 million    
5/5/2022Q1 2022($0.39)($0.40)($0.01)($0.40)$50.59 million$49.92 million
2/23/2022Q4 2021($0.31)($0.40)($0.09)($0.70)$48.18 million$47.16 million
11/2/20219/30/2021($0.29)($0.33)($0.04)($0.33)$37.75 million$40.99 million    
8/5/20216/30/2021($0.22)($0.24)($0.02)($0.24)$31.37 million$49.96 million    
5/6/20213/31/2021($0.26)($0.36)($0.10)($0.36)$12.80 million$19.06 million  
2/24/202112/31/2020($0.25)($0.34)($0.09)($0.34)$14.72 million$4.02 million  
11/5/20209/30/2020($0.25)($0.26)($0.01)($0.26)$4.31 million$6.10 million  
8/6/20206/30/2020($0.28)($0.24)+$0.04($0.24)$3.17 million$2.87 million  
5/6/20203/31/2020($0.24)($0.24)($0.24)$2.71 million$4.82 million  
3/5/202012/31/2019($0.26)($0.02)+$0.24($0.02)$12.02 million$39.73 million  
11/6/2019Q3($0.31)($0.34)($0.03)($0.34)$4.54 million$1.78 million  
8/6/2019Q2 2019($0.31)($0.34)($0.03)($0.34)$2.52 million$1.45 million
5/8/20193/31/2019($0.28)($0.28)($0.28)$2.92 million$5.89 million
3/4/201912/31/2018($0.26)($0.25)+$0.01($0.25)$2.39 million$2.73 million
11/6/20189/30/2018($0.25)($0.28)($0.03)($0.28)$2.53 million$1.45 million
8/7/2018Q2 2018($0.24)($0.19)+$0.05($0.19)$3.80 million$12.49 million
5/8/2018Q1 2018($0.16)($0.26)($0.10)($0.26)$10.20 million$3.98 million
2/27/2018Q4 2017($0.14)($0.20)($0.06)($0.20)$6.07 million$3.89 million  
11/7/2017Q3 2017($0.18)($0.18)($0.18)$5.05 million$8.76 million
8/7/2017Q2 2017($0.19)($0.21)($0.02)($0.21)$5.79 million$3.10 million  
5/4/2017Q1 2017($0.20)($0.19)+$0.01($0.19)$6.13 million$9.40 million  
2/27/2017Q416($0.23)($0.06)+$0.17($0.06)$4.13 million$9.00 million  
11/7/2016Q316($0.24)($0.16)+$0.08($0.16)$5.94 million$7.80 million  
8/4/2016Q216($0.26)($0.22)+$0.04($0.22)$3.92 million$4.80 million
5/5/2016Q116($0.23)($0.31)($0.08)($0.31)$5.42 million$4.82 million
2/23/2016Q415($0.26)($0.25)+$0.01($0.25)$6.34 million$4.60 million  
11/5/2015Q315($0.20)($0.20)($0.20)$6.77 million$11.00 million  
8/7/2015Q215($0.22)$0.06+$0.28$0.06$7.10 million$25.80 million  
5/8/2015Q115($0.24)($0.21)+$0.03($0.21)$4.30 million$6.80 million  
2/18/2015Q414($0.20)($0.16)+$0.04($0.16)$3.64 million$5.40 million  
11/6/2014Q314($0.20)($0.12)+$0.08($0.12)$2.11 million$3.20 million  
8/5/2014Q214($0.19)($0.23)($0.04)($0.23)$2.32 million$1.50 million  
5/8/2014Q114($0.16)($0.17)($0.01)($0.17)$3.34 million$3.50 million
2/26/2014Q4 2013($0.11)($0.09)+$0.02($0.09)$8.81 million$10.60 million
11/5/2013Q3 2013($0.13)($0.14)($0.01)($0.14)$2.01 million$2.40 million  
8/8/2013Q2 2013($0.12)($0.23)($0.11)($0.23)$2.01 million$0.82 million
5/7/2013Q1 2013($0.12)($0.09)+$0.03($0.09)$1.31 million$3.60 million
2/19/2013Q4 2012($0.16)($0.22)($0.06)$4.02 million$4.10 million
11/8/2012Q312($0.22)($0.19)+$0.03$4.63 million$5.80 million
8/2/2012($0.26)($0.25)+$0.01
5/7/2012($0.26)($0.13)+$0.13
2/16/2012($0.33)($0.29)+$0.04  
11/2/2011($0.30)($0.32)($0.02)  
8/4/2011($0.26)($0.36)($0.10)
5/4/2011($0.20)($0.29)($0.09)
2/10/2011($0.21)($0.20)+$0.01
10/28/2010Q3 2010($0.17)($0.24)($0.07)($0.24)
8/5/2010Q2 2010($0.24)($0.23)+$0.01($0.23)
4/28/2010Q1 2010($0.16)($0.06)+$0.10($0.06)
2/4/2010Q4 2009$0.08$0.35+$0.27$0.35
10/29/2009Q3 2009($0.22)($0.28)($0.06)($0.28)
7/30/2009Q2 2009($0.25)($0.23)+$0.02($0.23)
5/8/2009Q1 2009($0.28)($0.24)+$0.04($0.24)
2/6/2009Q4 2008($0.22)$0.26+$0.48$0.26
10/31/2008Q3 2008($0.25)($0.24)+$0.01($0.24)
8/7/2008Q2 2008($0.20)($0.33)($0.13)($0.33)
5/8/2008Q1 2008($0.16)($0.34)($0.18)($0.34)
3/4/2008Q4 2007($0.39)($0.06)+$0.33($0.06)












BioCryst Pharmaceuticals Earnings - Frequently Asked Questions

When is BioCryst Pharmaceuticals's earnings date?

BioCryst Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 3rd, 2023 based off last year's report dates. Learn more on BCRX's earnings history.

Did BioCryst Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) reported ($0.28) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.30) by $0.02. Learn more on analysts' earnings estimate vs. BCRX's actual earnings.

How can I listen to BioCryst Pharmaceuticals's earnings conference call?

The conference call for BioCryst Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read BioCryst Pharmaceuticals's conference call transcript?

The conference call transcript for BioCryst Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does BioCryst Pharmaceuticals generate each year?

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded annual revenue of $270.83 million.

How much profit does BioCryst Pharmaceuticals generate each year?

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded net income of -$247.12 million. BCRX has generated -$1.21 earnings per share over the last four quarters.

What is BioCryst Pharmaceuticals's EPS forecast for next year?

BioCryst Pharmaceuticals's earnings are expected to grow from ($1.03) per share to ($0.48) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:BCRX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -